Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.

Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol. 2019 Mar 28;: Authors: Puig L Abstract INTRODUCTION: IL-23 is the key regulatory cytokine of T17-mediated inflammation in psoriasis. Guselkumab is a subcutaneously administered monoclonal antibody that targets the p19 cytokine subunit in IL-23 and has been approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of moderate-to-severe psoriasis in adult patients. Areas covered: This review outlines the pharmacologic properties, efficacy and safety of guselkumab for the treatment of moderate-to-severe plaque psoriasis in adults. A literature review was performed by searching PubMed. Expert commentary: In clinical trials, guselkumab markedly improved disease, regardless of topographical locations and patient subpopulations, with corresponding improvements in quality of life measures, and was generally well tolerated. Guselkumab has been shown to be more effective than adalimumab in phase III pivotal trials (VOYAGE 1 and VOYAGE 2) at both week 16 and week 24 for PASI75, PASI90, PASI100 and IGA(0/1); the corresponding PASI 90 response rates at week 16 were 73.3% vs 49.7% in VOYAGE 1 and 70.0% vs 46.8% in VOYAGE 2 (P<0.001 in both). Guselkumab has also been shown to be superior to secukinumab in PASI90 response rate at week 48 in a head-to-head trial (ECLIPSE); it is also successful in trea...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research